BR9911043A - Composição para o tratamento do hiv e outras infecções viróticas - Google Patents

Composição para o tratamento do hiv e outras infecções viróticas

Info

Publication number
BR9911043A
BR9911043A BR9911043-1A BR9911043A BR9911043A BR 9911043 A BR9911043 A BR 9911043A BR 9911043 A BR9911043 A BR 9911043A BR 9911043 A BR9911043 A BR 9911043A
Authority
BR
Brazil
Prior art keywords
hiv
treatment
virus
hydrogen
carbon atoms
Prior art date
Application number
BR9911043-1A
Other languages
English (en)
Inventor
James Berger Camden
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of BR9911043A publication Critical patent/BR9911043A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Patente de Invenção: <B>"COMPOSIçãO PARA O TRATAMENTO DO HIV E OUTRAS INFECçõES VIRóTICAS"<D>. Uma composição farmacêutica que pode ser usada para o tratamento de infecções viróticas, de forma específica do HIV. A composição compreende a partir de cerca de 250 mg até cerca de 6000 mg de um derivado de benzimidazol da fórmula (I) ou um sal de adição, orgânico ou inorgânico, farmaceuticamente aceitável da mesma na qual X é hidrogênio, halogênio, alquila de menos do que 7 átomos de carbono ou alcóxi de menos do que 7 átomos de carbono; n é um número inteiro positivo de menos do que 4; Y é hidrogênio, cloro, nitro, oxicloro, metila ou etila; R é hidrogênio ou um grupo alquila a partir de 1 até 8 átomos de carbono; e R~ 2~ é 4-tiazolila. O composto de preferência é o tiabendazol. Na presente invenção foi descoberto que os compostos descritos acima são úteis para a inibição do HIV e para o tratamento da infecção por HIV quando usado de forma isolada ou em combinação com outro agente antivirótico. Essas composições podem impedir a replicação do vírus do HIV, impedir a criação de cepas de vírus que sejam resistentes ao tratamento com os benzimidazóis, impedir ou retardar a infecção de células com o vírus do HIV e retardar o reaparecimento do vírus em células tratadas. Essas composições também são eficazes contra a hepatite e vírus tais como os do herpes, influenza e rinovírus.
BR9911043-1A 1998-05-19 1999-05-19 Composição para o tratamento do hiv e outras infecções viróticas BR9911043A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8138498A 1998-05-19 1998-05-19
PCT/US1999/011059 WO1999059585A1 (en) 1998-05-19 1999-05-19 Compositions for the treatment of hiv and other viral infections

Publications (1)

Publication Number Publication Date
BR9911043A true BR9911043A (pt) 2001-02-13

Family

ID=22163807

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9911043-1A BR9911043A (pt) 1998-05-19 1999-05-19 Composição para o tratamento do hiv e outras infecções viróticas

Country Status (19)

Country Link
US (1) US6245789B1 (pt)
EP (1) EP1079831A1 (pt)
JP (1) JP2002515432A (pt)
KR (1) KR20010043709A (pt)
CN (1) CN1301158A (pt)
AR (1) AR019305A1 (pt)
AU (1) AU4004299A (pt)
BR (1) BR9911043A (pt)
CA (1) CA2329877A1 (pt)
CO (1) CO5050303A1 (pt)
HU (1) HUP0103319A2 (pt)
ID (1) ID27457A (pt)
IL (1) IL139002A0 (pt)
NO (1) NO20005839L (pt)
PE (1) PE20000550A1 (pt)
PL (1) PL344223A1 (pt)
SK (1) SK17442000A3 (pt)
TR (1) TR200003383T2 (pt)
WO (1) WO1999059585A1 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262093B1 (en) 1995-04-12 2001-07-17 The Proctor & Gamble Company Methods of treating cancer with benzimidazoles
US6479526B1 (en) 1995-04-12 2002-11-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US5770616A (en) 1995-06-07 1998-06-23 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
US6265427B1 (en) 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
US6686391B2 (en) 1995-08-04 2004-02-03 University Of Arizona Foundation N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
US6506783B1 (en) * 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US6245789B1 (en) 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
US6423734B1 (en) * 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
US6242461B1 (en) * 2000-01-25 2001-06-05 Pfizer Inc. Use of aryl substituted azabenzimidazoles in the treatment of HIV and AIDS related diseases
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
US6380232B1 (en) 2000-09-26 2002-04-30 The Procter & Gamble Company Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
US6462062B1 (en) * 2000-09-26 2002-10-08 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6608096B1 (en) * 2000-09-26 2003-08-19 University Of Arizona Foundation Compounds and methods for use thereof in the treatment of cancer or viral infections
US6407105B1 (en) * 2000-09-26 2002-06-18 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
WO2002041891A2 (en) * 2000-11-01 2002-05-30 The Procter & Gamble Company Hiv treatment with benzimidazoles
US6919352B2 (en) 2000-12-15 2005-07-19 Smithkline Beecham Corporation Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds
DE60112330T2 (de) 2000-12-15 2006-04-13 Glaxo Group Ltd., Greenford Pyrazolopyridinderivate
ATE274515T1 (de) 2001-03-08 2004-09-15 Smithkline Beecham Corp Pyrazolopyridinderivate
EP1372643A1 (en) 2001-03-30 2004-01-02 Smithkline Beecham Corporation Pyrazolopyridines, process for their preparation and use as therapeutic compounds
DE60212949T2 (de) 2001-04-10 2007-01-04 Smithkline Beecham Corp. Antivirale pyrazolopyridin verbindungen
ATE296826T1 (de) 2001-04-27 2005-06-15 Smithkline Beecham Corp Pyrazolo(1,5)pyridinderivate
PL366827A1 (en) * 2001-06-21 2005-02-07 Smithkline Beecham Corporation Imidazo[1,2-a]pyridine derivatives for the prophylaxis and treatment of herpes viral infections
WO2003031446A1 (en) 2001-10-05 2003-04-17 Smithkline Beecham Corporation Imidazo-pyridine derivatives for use in the treatment of herpes viral infection
WO2003050120A1 (en) * 2001-12-11 2003-06-19 Smithkline Beecham Corporation Pyrazolo-pyridine derivatives as antiherpes agents
JP2005521712A (ja) * 2002-03-26 2005-07-21 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ 弱塩基の可溶化
WO2004033454A1 (en) 2002-10-03 2004-04-22 Smithkline Beecham Corporation Therapeutic compounds based on pyrazolopyridine derivatives
AU2003900064A0 (en) * 2003-01-09 2003-01-23 Penam Investments Pty. Ltd. A method of treatment or prophylaxis of viral infection.
JP2005060362A (ja) * 2003-07-28 2005-03-10 Shionogi & Co Ltd セスキテルペン誘導体を含有する抗HIV剤、抗BVDV剤、抗HCV剤又は抗CoV剤
EP2251010A1 (en) 2009-05-08 2010-11-17 Sygnis Bioscience GmbH & Co. KG Use of thiabendazole and derivatives thereof for the therapy of neurological conditions
US9655962B2 (en) * 2013-03-15 2017-05-23 Camas Incorporated Methods and compositions for reducing microorganisms in the oropharynx, nasopharynx and oral cavities
FR3057865A1 (fr) * 2016-10-21 2018-04-27 Laboratoire Michel Iderne Composition chimique
TW201936193A (zh) * 2017-12-05 2019-09-16 愛爾蘭商健生科學愛爾蘭無限公司 使用組合產品治療rsv
KR102342313B1 (ko) * 2021-08-27 2021-12-24 (주)바이오메트릭스 테크놀로지 벤지미다졸-탄수화물 결합체 화합물을 포함하는 미셀, 이의 제조방법, 이의 항암제 또는 항바이러스제로서의 용도

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3010968A (en) 1959-11-25 1961-11-28 Du Pont Process for manufacture of certain alkyl esters of benzimidazole carbamic acids
NL134354C (pt) 1963-05-23
US3499761A (en) 1964-07-20 1970-03-10 Gaf Corp Silver halide emulsions containing alkyl esters of benzimidazole carbamic acid antifogging agents
US3541213A (en) 1966-05-06 1970-11-17 Du Pont Fungicidal and mite ovicidal substituted 2-aminobenzimidazoles
US3881014A (en) 1968-11-05 1975-04-29 Bayer Ag N-tritylimidazoles for treating fungal infections
BE759337A (fr) 1969-11-24 1971-05-24 Lilly Co Eli Benzimidazol (2,1-b)-quinazolin (6h) ones qui sont des immuno-depresseurs, et nouvelles benzimidazo (2,1-b) quinazolin-12-(6h) ones
US3956262A (en) 1970-12-09 1976-05-11 Beecham Group Limited Triazenoimidazoles
US3738995A (en) 1971-05-14 1973-06-12 Du Pont Solvent process for the preparation of 1 - carbamoyl-substituted 2 - benzimidazolecarbamates
FR2155888A1 (en) 1971-10-13 1973-05-25 Agot Aime Solid anthelmintic composn - for more economical treatment of ruminants
US4046906A (en) 1973-04-21 1977-09-06 Hoechst Aktiengesellschaft Salts of alkyl 2-benzimidazole-carbamate
HU193951B (en) 1985-03-11 1987-12-28 Richter Gedeon Vegyeszet Process for producing new sulfur-containing 5-substituted benzimidazol derivatives and pharmaceutical compositions containing them
US4731366A (en) 1986-08-05 1988-03-15 Harbor Branch Oceanographic Institution, Inc. Discorhabdin compositions and their methods of use
GB2210875B (en) 1987-10-09 1991-05-29 Farmos Oy Aromatase inhibiting 4(5)-imidazoles
US5329012A (en) 1987-10-29 1994-07-12 The Research Foundation Of State University Of New York Bis(acyloxmethyl)imidazole compounds
US5114951A (en) 1989-04-11 1992-05-19 Burroughs Wellcome Company Agents for combating multiple drug resistance
US5149527A (en) 1990-09-18 1992-09-22 Oncotech, Inc. Immunopotentiating protocol for chemotherapy-responsive tumors
US5310748A (en) 1992-05-11 1994-05-10 The Du Pont Merck Pharmaceutical Company Imidazoles for the treatment of atherosclerosis
US5364875A (en) 1992-05-11 1994-11-15 The Du Pont Merck Pharmaceutical Company Imidazoles linked to bicyclic heterocyclic groups for the treatment of atherosclerosis
US5290801A (en) 1992-05-29 1994-03-01 The Du Pont Merck Pharmaceutical Company Benzimidazoles for the treatment of atherosclerosis
CA2140653A1 (en) 1992-08-12 1994-03-03 Irene Abraham Protein kinase inhibitors and related compounds combined with taxol
KR100311551B1 (ko) 1993-03-31 2001-12-28 폴락 돈나 엘. Aids 치료용 약제학적 배합물 중의 hiv 프로테아제 억제제
US5434163A (en) 1993-05-14 1995-07-18 The Medical College Of Pennsylvania Treatment of Cryptococcus neoformans infection
JP3213471B2 (ja) 1994-04-13 2001-10-02 ポーラ化成工業株式会社 薬効成分含有リポソーム製剤の製造方法
ZA962880B (en) 1995-04-12 1997-03-17 Procter & Gamble A pharmaceutical composition for inhibiting the growth of viruses and cancers
US5656615A (en) 1995-04-12 1997-08-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers and viruses in mammals
US5665713A (en) 1995-04-12 1997-09-09 Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
ATE367808T1 (de) 1995-04-12 2007-08-15 Uaf Technologies And Res Llc N-chlorphenylcarbamate enthaltendes arzneimittel sowie n-chlorphenylthiocarbamate zur hemmung des wachstums von viren
ZA962879B (en) 1995-04-12 1997-03-17 Procter & Gamble A pharmaceutical composition for inhibiting the growth of viruses and cancers
US5629341A (en) 1995-04-12 1997-05-13 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
NZ305784A (en) 1995-04-12 2001-03-30 Procter & Gamble Benzimidazole containing medicaments for treating cancers, tumors and viral infections
US6200992B1 (en) 1995-06-07 2001-03-13 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
MX9707809A (es) 1995-06-07 1998-01-31 Procter & Gamble Una composicion farmaceutica que contiene bencimidazol para inhibir el crecimiento de canceres.
HUP9802634A3 (en) 1995-06-07 1999-05-28 Procter & Gamble Use of benzimidazoles for the manufacture of pharmaceutical compositions for the treatment of leukemia
US5665751A (en) 1995-06-07 1997-09-09 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
US5770616A (en) 1995-06-07 1998-06-23 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
SK14298A3 (en) 1995-08-03 1998-09-09 Procter & Gamble Use of griseofulvin for inhibiting the growth of cancers
CZ33798A3 (cs) 1995-08-04 1998-06-17 The Procter & Gamble Company Použití flukonazolu pro inhibování růstu rakovin
US5908855A (en) 1996-07-16 1999-06-01 The Procter & Gamble Company Compositions for treating viral infections
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
PE11499A1 (es) 1997-05-16 1999-03-01 Procter & Gamble Tratamiento del hiv y cancer
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US6245789B1 (en) 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment

Also Published As

Publication number Publication date
PL344223A1 (en) 2001-10-08
JP2002515432A (ja) 2002-05-28
AU4004299A (en) 1999-12-06
NO20005839L (no) 2001-01-16
AR019305A1 (es) 2002-02-13
US6245789B1 (en) 2001-06-12
SK17442000A3 (sk) 2001-08-06
CO5050303A1 (es) 2001-06-27
IL139002A0 (en) 2001-11-25
EP1079831A1 (en) 2001-03-07
CA2329877A1 (en) 1999-11-25
HUP0103319A2 (hu) 2002-05-29
WO1999059585A1 (en) 1999-11-25
NO20005839D0 (no) 2000-11-17
TR200003383T2 (tr) 2001-03-21
ID27457A (id) 2001-04-12
CN1301158A (zh) 2001-06-27
KR20010043709A (ko) 2001-05-25
PE20000550A1 (es) 2000-06-29

Similar Documents

Publication Publication Date Title
BR9911043A (pt) Composição para o tratamento do hiv e outras infecções viróticas
BR0312271A (pt) compostos, composições e seus usos para o tratamento de infecções por flaviviridae
TW427887B (en) Pharmaceutical composition comprising a benzimidazole derivative for treating viral infections
UY27466A1 (es) Métodos y composiciones para el tratamiento de hepatitis c virus con 4&#39;-modificaciones nucleosides
CL2008003431A1 (es) Compuestos derivados de nucleosidos 2&#39;,4&#39; sustituidos; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; su metodo de preparacion; y su uso para el tratamiento y/o la prevencion de cualquier condicion resultante de una infeccion por vhb, vhc o vih.
EA200800932A1 (ru) Модифицированные 4`-нуклеозиды в качестве противовирусных агентов
CO5200778A1 (es) Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de b enzimidazol, administrada para prevenir y tratar el cancer e inhibir la metastasis
BRPI0510414A (pt) uso de derivados de quinolina substituìdos para o tratamento de doenças micobacterianas resistentes a fármacos
BR0213522A (pt) Composto, composição farmacêutica, métodos de inibir a hiv integrase e para prevenir ou tratar a infecção pelo hiv ou para prevenir, tratar ou retardar o inìcio da aids em um paciente, e, combinação útil para tratar ou prevenir a infecção pelo hiv ou para prevenir, tratar ou retardar o inìcio da aids
WO2008132138A9 (en) AMINOPYRIMIDINE DERIVATIVES DISUBSTITUTED IN 4 AND 6
MX2009005120A (es) Compuestos quimicos.
MA27329A1 (fr) Promedicaments a nucleosides 2&#39; et 3&#39; destines a traiter les infections aux flavivirus
BR9912896A (pt) Nucleotìdeos beta-l-2&#39; -dioxi para tratamento de hepatite b
HUP0001170A2 (hu) Hatóanyagként enzimidazol-2-karbamát-származékokat tartalmazó, vírusfertőzések és rák kezelésére alkalmas gyógyszerkészítmények
EA200500846A1 (ru) Замещенные арилтиомочевины и родственные соединения; ингибиторы вирусной репликации
AR019505A1 (es) Composicion farmaceutica y usos de la misma para tratar infecciones virales
BRPI0508079A (pt) composto ou uma forma cristalina ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, métodos de tratar ou prevenir uma infecção viral com hepatite c em um mamìfero e de inibir replicação de um vìrus da hepatite c
BRPI0412502A (pt) derivados de ariltiouréia substituìda úteis como inibidores de replicação viral
BR0107912A (pt) Composto, composições, e, métodos para tratar ou prevenir o c ncer ou doença neoplástica, método para inibir o desenvolvimento de uma célula cancerìgena ou célula neoplástica, método para tratar ou prevenir uma infecção viral em um paciente, e para inibir a replicação ou a infectividade de um vìrus
AR018706A1 (es) Uso de una composicion farmaceutica para tratamiento de infecciones virales
WO2007106450A3 (en) Diketo acids with nucleobase scaffolds: anti-hiv replication inhibitors targeted at hiv integrase in combination therapy
BR0314695A (pt) Composto, processo para preparar um composto, processo para preparar um estereoisÈmero de um composto, composição para o tratamento de doenças virais, e, composição para o tratamento da hepatite b
AR003137A1 (es) Una composicion farmaceutica para tratar la leucemia
KR910000734A (ko) 네플라노신 유도체
JP2023518390A (ja) ウイルス感染症の治療若しくは予防又はウイルス感染症の発生を制限するための方法及び組成物

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A, 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007.